SCHEMBL16132001

SCHEMBL16132001

Cc1ccc(N2CCC(N3CCOCC3)C2)nn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.52
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HTT P42858 1/20 0.45
SMPD3 Q9NY59 1/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
CNR2 P34972 2/20 0.41
KDM4E B2RXH2 4/20 0.38
MAPT P10636 3/20 0.38
HPGD P15428 3/20 0.38
CASP1 P29466 3/20 0.38
HSD17B10 Q99714 3/20 0.38
LMNA P02545 2/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
CASP7 P55210 2/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18291646 0.91 ALDH1A1 (0.50) MAP4K4ALDH1A1SMN1; SMN2HTTCYP3A4
SCHEMBL13279548 0.84 MAP4K4 (0.57) MAP4K4ALDH1A1SMN1; SMN2HTTCYP3A4
SCHEMBL13466376 0.84 MAP4K4 (0.48) MAP4K4ALDH1A1SMN1; SMN2HTTSMPD3
SCHEMBL11981452 0.80 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2HTTCNR2KDM4E
Ammonia Solution, Strong SCHEMBL27696045 0.78 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2HTTCNR2KDM4E
SCHEMBL20249266 0.78 MAP4K4 (0.42) MAP4K4ALDH1A1SMN1; SMN2HTTCYP3A4
SCHEMBL18291244 0.75 MAP4K4 (0.47) MAP4K4ALDH1A1SMN1; SMN2HTTCYP3A4
SCHEMBL1781248 0.75 MAP4K4 (0.53) MAP4K4ALDH1A1SMN1; SMN2HTTCYP2C9
SCHEMBL15651882 0.75 MAP4K4 (0.59) MAP4K4ALDH1A1SMN1; SMN2HTTCYP2C9
SCHEMBL10289476 0.75 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2HTTCNR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140288044-A1 COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) 2014-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288044-A1 COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS CSNK1G1, PRKCE, PHKG1 MAP4K4 295/4885ALDH1A1 4487/4885SMN1; SMN2 3119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.